|Project Title||Principal Investigator||Institution|
|Role of a novel Wnt pathway in autism spectrum disorders||Reichardt, Louis||University of California, San Francisco|
|The genetics of restricted, repetitive behavior: An inbred mouse model||Lewis, Mark||University of Florida|
|The genetic control of social behavior in the mouse||Blanchard, Robert||University of Hawai'i at Manoa|
|A comparative developmental connectivity study of face processing||Joseph, Jane||University of Kentucky|
|A mouse knock-in model for ENGRAILED 2 autism susceptibility||Millonig, James||University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School|
|Serotonin, corpus callosum, and autism||Lin, Rick||University of Mississippi Medical Center|
|Characterization of a novel mouse model of restricted repetitive behaviors||Moy, Sheryl||University of North Carolina at Chapel Hill|
|Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders||Malanga, C.J.||University of North Carolina School of Medicine|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|Neurobiology of sociability in a mouse model system relevant to autism||Brodkin, Edward||University of Pennsylvania|
|Neurobiology of sociability in a mouse model system relevant to autism (supplement)||Brodkin, Edward||University of Pennsylvania|
|Behavioral and physiological consequences of disrupted Met signaling||Levitt, Pat||University of Southern California|
|Dysregulation of PI3K/AKT in social interaction deficits and autism spectrum disorders with macrocephaly||Parada, Luis||University of Texas Southwestern Medical Center|
|Novel genetic animal models of autism||Powell, Craig||University of Texas Southwestern Medical Center|
|Animal models of autism: Pathogenesis and treatment||Powell, Craig||University of Texas Southwestern Medical Center|
|Transgenic mouse model to address heterogeneity in autism spectrum disorders||Blakely, Randy||Vanderbilt University|
|Mouse genetic model of a dysregulated serotonin transporter variant associated with autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|Using zebrafish and chemical screening to define function of autism genes||Sive, Hazel||Whitehead Institute for Biomedical Research|
|Caspr2 dysfunction in autism spectrum disorders||Robbins, Elissa||Yale University|
|Integrated approach to the neurobiology of autism spectrum disorders||Vaccarino, Flora||Yale University|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.